Roivant Sciences Ltd
For the period ended Dec 31, 2024. Filed Feb 10, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2024 · Filed Feb 10, 2025
ROIV$38.88+6.2%Stored close · as of Nov 6, 2026
Contents
Condensed Consolidated Balance Sheets as of December 31, 2024 and March 31, 2024
CondensedConsolidatedBalance Sheets
(unaudited, in thousands, except share and per share amounts)
| December 31, 2024 | March 31, 2024 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $1,990,683 | $6,494,953 |
| Marketable securities | 3,155,825 | — |
| Other current assets | 217,460 | 80,605 |
| Current assets of discontinued operations (Note 6) | — | 156,270 |
| Total current assets | 5,363,968 | 6,731,828 |
| Property and equipment, net | 13,563 | 15,322 |
| Operating lease right-of-use assets | 90,895 | 44,002 |
| Investments measured at fair value | 290,040 | 247,753 |
| Other assets | 33,879 | 37,701 |
| Noncurrent assets of discontinued operations (Note 6) | — | 145,876 |
| Total assets | $5,792,345 | $7,222,482 |
| Liabilities and Shareholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $23,712 | $14,029 |
| Accrued expenses | 104,324 | 119,417 |
| Operating lease liabilities | 9,835 | 8,966 |
| Other current liabilities | 3,613 | 13,941 |
| Current liabilities of discontinued operations (Note 6) | — | 110,405 |
| Total current liabilities | 141,484 | 266,758 |
| Liability instruments measured at fair value | 24,105 | 25,737 |
| Operating lease liabilities, noncurrent | 90,479 | 45,020 |
| Other liabilities | 307 | 2,493 |
| Noncurrent liabilities of discontinued operations (Note 6) | — | 433,945 |
| Total liabilities | 256,375 | 773,953 |
| Commitments and contingencies (Note 11) | ||
| Shareholders’ equity: | ||
| Common shares, par value $0.0000000341740141 per share, 7,000,000,000 shares authorized and 719,632,367 and 806,677,954 shares issued and outstanding at December 31, 2024 and March 31, 2024, respectively | — | — |
| Additional paid-in capital | 4,721,017 | 5,396,492 |
| Retained earnings | 460,398 | 576,172 |
| Accumulated other comprehensive income (loss) | 8,057 | (4,083) |
| Shareholders’ equity attributable to Roivant Sciences Ltd. | 5,189,472 | 5,968,581 |
| Noncontrolling interests | 346,498 | 479,948 |
| Total shareholders’ equity | 5,535,970 | 6,448,529 |
| Total liabilities and shareholders’ equity | $5,792,345 | $7,222,482 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.